4CPS-186 Therapeutic drug monitoring of tyrosine kinase inhibitors: key to personalised medicine in oncology. (March 2019)

• Record Type: Journal Article
• Authors: Chetouane, K; Debrix, I
• Is Part Of: European journal of hospital pharmacy. Volume 26(2019)Supplement 1
• Page Start: A156
• Page End: A156
• Publication Date: 2019-03
• Subjects: Pharmacy -- Periodicals; Hospital pharmacies -- Periodicals; 615.1
• DOI: 10.1136/ejhpharm-2019-eahpconf.335
• Languages: English
• ISSNs: 2047-9956

Abstract

Abstract : Background: Tyrosine kinase inhibitors (TKIs) are increasingly used as oral targeted therapies in oncology. However, the oral route leads to a high interindividual pharmacokinetic variability. Thus, in order to improve efficacy and/or reduce toxicity, therapeutic drug monitoring (TDM) can be used to adapt doses and personalise treatments. 1 2 Purpose: To assess the potential impact of TDM on clinical decisions in patients treated with TKIs. Material and methods: Retrospective study from January to October 2018 including patients treated for solid tumours with TKIs. Blood samples were collected and analysed to determine TKIs trough plasma concentrations 3 to 15 days after administration depending on the TKI (necessary time to reach targeted steady state). All patients were initiated at the recommended daily dose of TKIs. Doses were then adjusted based on efficacy, toxicity and TDM outcomes. In case of failure on TKIs, patients were administered a second-line therapy or another TKI. The evaluated criteria were: patients' characteristics, concomitant treatments, patients' plasma exposure, medical decision, tolerance and disease progression. Results: In total, we collected and analysed 73 blood samples, of which 61.6% were an anti-estimated glomerular filtration rate (afatinib, osimertinib, gefitinib, erlotinib), 21.9% anti-CDK4/6 drug (palbociclib) and 16.4% anti-vascular endothelial growth factor drugs (cabozantinib, nintédanib, pazopanib, regorafenib, sunitinib). Sixty-two per cent (n=45) of the samples were within the therapeutic interval and most patients continued treatment. However, 10 cases were switched: eight because of disease progression and two due to toxicity. Despite subtherapeutic exposure (26%, n=19), treatment was continued without any dose escalation in nine cases, as the maximum authorised dosage was reached. On the other hand, supratherapeutic exposure (12%, n=9) required dose reduction of the TKI or treatment withdrawal in five cases while the other four had a good tolerance. TKIs are mostly well tolerated as 12 patients out of 45 reached the 1–2 toxicity grade and only two patients reached the 3–4 toxicity grade. Four drug-drug interactions have been identified after TDM. TKIs are essentially metabolised by cytochrome P450 enzymes. 3 Conclusion: This study suggests that TDM could help in daily clinical decisions along with other clinical data. Indeed, TDM helped us to detect supratherapeutic exposure and reduce toxicity, uncover drug interactions and optimise patient management to improve clinical outcomes. References and/or acknowledgements: 1. PMID: 24878063. 2. PMID: 27446421. 3. PMID: 24041628. No conflict of interest.